Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. TIDACT INJECTION 300MG/2ML [SIN07759P]

TIDACT INJECTION 300MG/2ML [SIN07759P]

Active ingredients: TIDACT INJECTION 300MG/2ML

Last updated 26 October 2025

Product Info

TIDACT INJECTION 300MG/2ML

[SIN07759P]

Product information

Active Ingredient and Strength

CLINDAMYCIN PHOSPHATE EQV CLINDAMYCIN - 150 MG/ML

Dosage Form

INJECTION

Manufacturer and Country

YUNG SHIN PHARMACEUTICAL IND CO LTD - TAIWAN

Registration Number

SIN07759P

Licence Holder

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J01FF01

Indications:
For the treatment of serious infections due to susceptible strains of Staphylococci, Streptococci, Pneumococci, and anaerobic bacteria.

Dosage and Administration:
Single I.M. injection should not exceed 600mg; for I.V. infusion, do not administer more than 1200mg in a single 1 hour infusion.
Adult dose: I.M. or I.V.
Ordinary infections: 600–1200mg/day in 2,3 or 4 equal doses.
Serious infections: 1200–1800mg/day in 3 or 4 equal doses.
Very serious infections: 2400–2700mg/day in 2,3 or 4 equal doses.
In life threatening situations, a maximum of 4800mg/day may be given I.V.
May be administered as a single rapid infusion on the first dose and followed by continuous I.V. infusion, as follows:
To maintain serum

Tidact Dosage Table 1



To prepare initial dilution for I.V. dose, each dose must be diluted as follows (it must not be administered undiluted as a bolus):

Tidact Dosage Table 2



Children dose: I.M. or I.V.
Infants up to 1 month of age: 15–20mg/kg/day in 3 or 4 equal doses.
Over 1 month of age: 20–40mg/kg/day in 3 or 4 equal doses.
May be given based on body surface area:
Serious infections: 350mg/m2/day
More serious infections: 450mg/m2/day
In β-hemolytic streptococcal infection, treatment should be continued for at least 10 days.
To be administered only by a physician.

Contraindications:

  1. History of gastrointestinal disease, especially ulcerative colitis, regional enteritis, and antibiotic-associated colitis. Clindamycin may cause pseudomembranous colitis.

  2. Severe hepatic function impairment. Half-life of Clindamycin is prolonged in this condition, therefore may require dosage adjustment.

  3. Hypersensitivity to Lincomycins and doxorubicin.

  4. Severe renal function impairment may require reduction of dosage.